Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) stock plunged by 6.49% at last close while the ORMP stock price fell by 1.15% in the after-hours trading. Oramed Pharmaceuticals is a leader in the area of orally administered solutions for pharmaceuticals that are now administered through injection. Oramed, which was founded in 2006 and has offices in the US and Israel, has developed a revolutionary Protein Oral Delivery (POD) technology.
ORMP stock’ Recent Development
Oramed Pharmaceuticals has registered more than half of the individuals in its Phase 2 trial of ORMD-0801, an oral insulin capsule for the treatment of non-alcoholic steatohepatitis (NASH). Patients are still being screened in the United States and Israel.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
- Looking For The Best Stocks To Buy For 2021? 3 Electric Vehicle Stocks To Watch
- Top 3 Cosmetics Stocks in the market
ORMD-0801’s safety and potential efficacy in Type 2 diabetic patients with NASH is being studied in a double-blind, multi-center experiment. Following 12 weeks of dosage, MRI-PDFF will be used to assess efficacy outcomes such as percentage change in liver fat content, hepatic fibrosis, and liver steatosis compared to baseline. By 2029, the world market for NASH medications is estimated to reach $84 billion.
Non-alcoholic steatohepatitis (NASH) is a dangerous, serious liver disease characterised by a build-up of fat in the liver, inflammation, liver cell destruction, and, in rare cases, liver scarring. NASH can lead to cirrhosis, liver cancer, liver failure, and even fatality over time. There is presently no globally authorised medication for the treatment of NASH, leaving patients with the disease with few treatment alternatives.
Oramed Chief Executive Officer, Nadav Kidron stated,
ORMD-0801 has the ability to enhance results for people with both NASH and diabetes, as more than half of NASH patients have diabetes. NASH is a disease with a substantial unmet medical need because no medications have been licenced to treat it, despite the fact that it is the primary cause of liver transplants in the United States. They’re thrilled to build on the findings of their pilot research, which demonstrated a decrease in liver fat content, to indicate that ORMD-0801 has the potential to benefit patients with NASH.